EKOS was the first product indicated for treatment of pulmonary embolism and can be used for therapeutics such as deep vein thrombosis or arterial occlusion.

Pulmonary embolism (PE) can be defined as the blockage of either the pulmonary arteries or its branches with embolic material (either air, fat, amniotic fluid or a thrombus) that originates elsewhere in the body.

A first-line pulmonary embolism intervention Backed by a decade of clinical evidence, including the only patient level long-term data and largest real-world dataset in the space, EKOS has been the safe and simple interventional treatment of choice for patients with PE.

When imaging confirms the presence of a pulmonary embolism (PE), physicians must determine the best treatment approach for each patient by taking a balanced look at the efficacy and safety of intervention.

EKOS Offers Great Benefits for High-Risk Pulmonary Embolism Patients. The EkoSonic Pulmonary Embolism (EKOS®) System is “so effective, even for the most complex cases, that it’s hard not to use it for all patients with pulmonary embolism [PE],” says Timothy Smith, MD. Dr.

Catheter-Directed Thrombolysis (EKOS) uses a combination of drugs and ultrasound waves to break up or dissolve major blood clots that cause pulmonary embolism. Using the EKOS EndoWave Infusion Catheter System®, Temple interventionists can restore blood flow and limit damage to the patient’s lungs, and potentially heart or brain.

TE EKOS™ AND EKOS+™ ENDOVASCULAR SYSTEMS EATURED TECNOLOGY Corporation W hen imaging confirms the presence of a pulmonary embolism (PE), physicians must determine the best treatment approach for each patient by taking a balanced look at the efficacy and safety of interven-tion. Several clinical and imaging factors can help

12-hour follow-up pulmonary angiograms post–EKOS infusion in early (a) and delayed (b) phases demonstrate interval thrombolysis bilaterally with significantly improved pulmonary perfusion and associated decreases in right ventricular and pulmonary pressures as well as the right ventricular/left ventricular ratio.

2022年8月12日 · One such catheter-based treatment known as “ultrasound-assisted thrombolysis” (UAT) involves the EKOS™ Catheter, a device that’s designed to: (1) deliver a clot-busting drug to dissolve existing clots; and (2) use energy from sound waves to spread the drug out within the clot.

EKOS was the first interventional device cleared for treating pulmonary embolism. Today, it’s trusted by more clinicians than any other PE device. Proven to yield safe and effective results, EKOS is low risk and reliable. Because of EKOS’ small size, it allows further reach into smaller distal pulmonary vessels.